PepBear

EDUCATIONAL LIBRARY

Tesamorelin

Growth-hormone-releasing-hormone analogue.

Aliases: egrifta

Half-life context

0.18333333333333332 hours. About eleven minutes for the labeled Egrifta WR formulation in healthy subjects; formulations differ.

Regulatory status

Checked 2026-10-09

FDA product approval

approved product. Egrifta WR, for its labeled HIV-associated indication.

Compounding

not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.

Research status

product specific. Adults with HIV-associated lipodystrophy and excess abdominal fat; not general weight loss.

Sport status

prohibited. WADA S2 lists this GHRH analogue.

Evidence A

Established human clinical or approved-product evidence for the specified indication.

Grades describe the cited population and indication, not safety or suitability for an individual.

Population: Adults with HIV-associated lipodystrophy and excess abdominal fat; not general weight loss.

Indication: Approved labeled indication only.

Basis: Product-label clinical evidence.

Risks

Contraindications

Interactions

What to record

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions.

Review: source-curated; clinician review pending

Sources

Where to buy

Optional partner links, separate from the research above.

Show partner links and codes

PepBear is operated by PepStar LLC, which earns commissions when you use these partner links or codes. These general merchant links are not source citations, treatment recommendations, or a statement that this compound is available or suitable for human use. Research-only products are not approved for human use. Your PepBear health records are not used to target these offers.

Limitless Biotech. Use discount code RICHPEP at checkout. Check current merchant terms.

Ascension Peptides. PepStar LLC earns a commission on referred sales.

LVLUP Health. Code: PEPBEAR. Check current merchant terms.